XOMA 052 Phase 2b Top Line Results: Glucose Control Not Demonstrated, Positive Anti-inflammatory Effect, Cardiovascular Biomarker and Lipid Improvement and Safety Confirmed Mar 22, 2011 4:20pm EDT
XOMA to Announce 2010 Fourth Quarter Financial Results and Host Conference Call on March 10 Mar 04, 2011 4:02pm EST
Interim Three Month Data From Ongoing Six Month XOMA 052 Phase 2a Trial Support Safety and Biological Activity Jan 06, 2011 4:59pm EST
XOMA and Servier Sign Development and Commercialization Agreement for XOMA 052 Jan 04, 2011 7:55am EST
XOMA to Host Conference Call and Webcast on January 4, 2011 to Provide Business Update Jan 03, 2011 6:41pm EST
